• 1
    Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107: 404752.
  • 2
    Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131: 3949.
  • 3
    Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood 2011; 117: 580315.
  • 4
    ROHA. Registro Oncopediátrico Hospitalario Argentino. Resultados 2000–2008., 3rd edn., Buenos Aires: Fundación Kaleidos, 2010.
  • 5
    Rickinson AB, Kieff ED. Epstein Barr virus. In: Knipe DM, Howley PM, eds. Fields virology, 5th edn., vol. 2. Philadelphia: Walters Kluwers/Lippincott Williams & Wilkins, 2007. 2655700.
  • 6
    Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4: 75768.
  • 7
    IARC. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn., vol. 2. Lyon: WHO Press, 2008.
  • 8
    Adam P, Bonzheim I, Fend F, et al. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011; 18: 34955.
  • 9
    Beltran BE, Castillo JJ, Morales D, et al. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol 2011; 86: 6637.
  • 10
    Hofscheier A, Ponciano A, Bonzheim I, et al. Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population. Mod Pathol 2011; 24: 104654.
  • 11
    Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 2007; 13: 512432.
  • 12
    Gibson SE, Hsi ED. Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype. Hum Pathol 2009; 40: 65361.
  • 13
    Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations. Hum Pathol 2010; 41: 3527.
  • 14
    Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16: 8796.
  • 15
    Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 9728.
  • 16
    Cacciatore M, Guarnotta C, Calvaruso C, et al. Microenvironment-centred dynamics in aggressive B-cell lymphomas. Adv Hematol, 2012; 2012: 138079.
  • 17
    de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 2008; 264: 52836.
  • 18
    Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 231323.
  • 19
    Linderoth J, Eden P, Ehinger M, et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 42332.
  • 20
    Barros MH, Vera-Lozada G, Soares FA, et al. Tumor microenvironment composition in pediatric classical Hodgkin lymphoma is modulated by age and Epstein-Barr virus infection. Int J Cancer 2012; 131: 114252.
  • 21
    Baumforth KR, Birgersdotter A, Reynolds GM, et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am J Pathol 2008; 173: 195204.
  • 22
    Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113: 27653775.
  • 23
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 27582.
  • 24
    Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
  • 25
    Kim JM, Rudensky A. The role of the transcription factor Foxp3 in the development of regulatory T cells. Immunol Rev 2006; 212: 8698.
  • 26
    Cool CD, Bitter MA. The malignant lymphomas of Kenya: morphology, immunophenotype, and frequency of Epstein-Barr virus in 73 cases. Hum Pathol 1997; 28: 102633.
  • 27
    Tumwine LK, Orem J, Kerchan P, et al. EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda. Infect Agent Cancer 2010; 5: 12.
  • 28
    Chabay PA, Barros MH, Hassan R, et al. Pediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol 2008; 30: 28591.
  • 29
    Chabay P, Lara J, Lorenzetti M, et al. Epstein Barr virus in relation to apoptosis markers and patients' outcome in pediatric B-cell non-Hodgkin lymphoma. Cancer Lett 2011; 307: 2216.
  • 30
    Chabay P, Burna V, Moar A, et al. Prevalencia de la infeccion por el virus de Epstein Barr en pacientes pediatricos. Rev Hosp Ninos 1999; 41: 8891.
  • 31
    Hsu JL, Glaser SL. Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000; 34: 2753.
  • 32
    Chabay PA, De Matteo EN, Aversa L, et al. Assessment of Epstein-Barr virus association with pediatric non-hodgkin lymphoma in immunocompetent and in immunocompromised patients in Argentina. Arch Pathol Lab Med 2002; 126: 3315.
  • 33
    Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. N Engl J Med 1996; 334: 123848.
  • 34
    Nadal D, Caduff R, Frey E, et al. Non-Hodgkin's lymphoma in four children infected with the human immunodeficiency virus. Association with Epstein-Barr Virus and treatment. Cancer 1994; 73: 22430.
  • 35
    Preciado MV, Fallo A, Chabay P, et al. Epstein Barr virus-associated lymphoma in HIV-infected children. Pathol Res Pract 2002; 198: 32732.
  • 36
    Anderton E, Yee J, Smith P, et al. Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 2008; 27: 42133.
  • 37
    Kasprzak A, Spachacz R, Wachowiak J, et al. Epstein-Barr virus (EBV) infection in B-cell non-Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia Histochem Cytobiol 2007; 45: 16979.
  • 38
    Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood 1995; 86: 65965.
  • 39
    Young LS, Dawson CW, Clark D, et al. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988; 69: 105165.
  • 40
    Nguyen-Van D, Keane C, Han E, et al. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8+ T-cell epitopes. Am J Blood Res 2011; 1: 14.
  • 41
    Rowe M, Kelly GL, Bell AI, et al. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 2009; 19: 37788.
  • 42
    Johannsen E, Koh E, Mosialos G, et al. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 1995; 69: 25362.
  • 43
    Kis LL, Gerasimcik N, Salamon D, et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. Blood 2011; 117: 16574.
  • 44
    Chapman AL, Rickinson AB, Thomas WA, et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001; 61: 621926.
  • 45
    Lee SP. Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Semin Cancer Biol 2002; 12: 46371.
  • 46
    Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 146773.
  • 47
    Lambert SL, Martinez OM. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007; 179: 822534.
  • 48
    Mahot S, Sergeant A, Drouet E, et al. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. J Gen Virol 2003; 84: 96574.
  • 49
    Samanta M, Iwakiri D, Takada K. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene 2008; 27: 415060.
  • 50
    Oudejans JJ, Jiwa NM, Kummer JA, et al. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997; 89: 137682.